USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
LOHOCLA RESEARCH CORPORATION
Address:
12635 E. Montview Blvd.
AURORA, CO 80045-7337
Phone:
N/A
URL:
N/A
EIN:
136331496
DUNS:
966627499
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,440,034.00 8
SBIR Phase II $2,093,521.00 2

Award List:

THE GOAL OF THIS PROJECT IS TO DEVELOP SIMPLE AND RELIABLE BIOCHEMICAL TESTS WHICH CAN BE USED TO IDENTIFY INDIVIDUALS AT RISK FOR ALCOHOLISM, AND/OR TO ACCURATELY INDICATE RECENT ALCOHOL ABUSE.

Award Year / Program / Phase:
1984 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Boris tabakoff
Abstract:
The goal of this project is to develop simple and reliable biochemical tests which can be used to identify individuals at risk for alcoholism, and/or to accurately indicate recent alcohol abuse. in phase i, the feasibility of using platelet enzymes as such markers will be assessed. our preliminary… More

THE APPLICATION'S LONG-TERM OBJECTIVE IS TO DEVELOP A MORE EFFECTIVE, SAFE, RELATIVELY LONG-TERM BARRIER CONTRACEPTIVE DEVICE.

Award Year / Program / Phase:
1985 / SBIR / Phase I
Award Amount:
$45,800.00
Agency:
HHS
Principal Investigator:
Robert a. anderson jr. , PRINCIPAL INVESTIGATOR
Abstract:
The application's long-term objective is to develop a more effective, safe, relatively long-term barrier contraceptive device. development of the proposed device will have significant impact on effective control of overpopulation and reduction of abortions secondary to unwanted pregnancies. the… More

Medications for Alcohol Withdrawal/Brain Damage

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$78,375.00
Agency:
HHS
Principal Investigator:
Lawrence Snell
Abstract:
N/a

Medications for Alcohol Withdrawal/Brain Damage

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$748,637.00
Agency:
HHS
Principal Investigator:
Lawrence Snell
Abstract:
Chronic ethanol ingestion results in neurodegeneration with loss of neurons, glial proliferation anventricular and subarachnoid space. Work from our laboratories has demonstrated that chronic ethanolanimals produces an up-regulation of the excitatory N-methyl-D-aspartate (NMDA) subtype of… More

N/A

Award Year / Program / Phase:
2000 / SBIR / Phase I
Award Amount:
$156,875.00
Agency:
HHS
Principal Investigator:
Lawrence D. Snell
Abstract:
N/a

Proteomic Markers of Alcohol Abuse (Phase 1)

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$396,228.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Alcohol dependence and hazardous levels of ethanol ingestion are under-diagnosed and under-reported. Significant effort has been expended to develop biological markers (diagnostics) for monitoring levels and/or recency of alcohol use (state markers) and markers… More

DEV OF CORRELATIONAL ALCOHOL-RELEVANT DATABASE

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$156,217.00
Agency:
HHS
Principal Investigator:
Boris Tabakoff
Abstract:
N/a

Proteomic Markers of Alcohol Abuse (Phase 1)

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$1,344,884.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Alcohol dependence and hazardous levels of ethanol ingestion are under-diagnosed and under-reported. Significant effort has been expended to develop biological markers (diagnostics) for monitoring levels and/or recency of alcohol use (state markers) and markers… More

Monoclonal antibody mediated biomarker discovery for alcohol-induced liver damage

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$240,065.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this SBIR application is to demonstrate the feasibility of a global approach to screen for disease specific monoclonal antibodies (mAbs) to low level proteins for the discovery and validation of biomarkers o f alcohol-induced liver damage. The… More

Small Molecule Inhibitors of the BCL6 Oncoprotein

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$316,474.00
Agency:
HHS
Principal Investigator:
Boris Tabakoff – 720-859-4083
Abstract:
DESCRIPTION (provided by applicant): Chronic pain syndromes affect 25-35% of populations around the world. The presence of chronic pain generates a massive toll on quality of life, workforce productivity and healthcare resource utilization. Although non-opiate medications have been introduced to… More